ImageneBio (IMA) Interest Coverage Ratio (2022 - 2023)
ImageneBio's (IMA) quarterly Interest Coverage Ratio came in at 1564.86 in Q4 2023, down 131.06% year-over-year from 5038.0 in Q4 2022, and up 83.95% quarter-over-quarter from 9751.5 in Q3 2023.
Powered by 
Analysis
ImageneBio (IMA) Interest Coverage Ratio (2022 - 2023) Analysis & Trends
ImageneBio has disclosed Interest Coverage Ratio across 2 years of filings, most recently posting 1564.86 for Q4 2023.
- In Q4 2023, Interest Coverage Ratio fell 131.06% year-over-year to 1564.86; the TTM figure through Dec 2023 stood at 3969.26 (down 487.81% YoY), while the FY2023 annual figure was 3428.05, up 51.65% from the prior year.
- Interest Coverage Ratio came in at 1564.86 for Q4 2023 at ImageneBio, up from 9751.5 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 5038.0 in Q4 2022 to a low of 9751.5 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | ImageneBio | 42.89 Mn | -92.46 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -1,564.86 |
| Sep 30, 2023 | -9,751.50 |
| Jun 30, 2023 | -3,081.67 |
| Dec 31, 2022 | 5,038.00 |
| Sep 30, 2022 | -1,489.67 |
| Jun 30, 2022 | -445.77 |
| Mar 31, 2022 | -346.16 |